Dr. John M. Lambert is a Consultant and Scientific Advisor and Honorary Professor at Queen’s University Belfast. He began his career at the Dana-Farber Cancer Institute and Harvard Medical School, where he was among the earliest scientists working on antibody-drug conjugates (ADCs) and immunotoxins for cancer therapy.

He held multiple senior leadership roles at ImmunoGen over a decades-long tenure, including Executive Vice President of Research and Chief Scientific Officer, and later Distinguished Research Fellow. During his tenure, ImmunoGen scientists pioneered ADC technologies that led to several approved therapies, including KADCYLA® for HER2-positive breast cancer, ELAHERE® for ovarian cancer, and SARCLISA® for multiple myeloma. His work has been instrumental in advancing ADCs as a transformative therapeutic modality in oncology.

Dr. Lambert has authored more than 125 peer-reviewed scientific publications and was elected a Fellow of the American Institute for Medical and Biological Engineering. He earned his PhD in Biochemistry from the University of Cambridge and completed postdoctoral training at the University of California, Davis and the University of Glasgow. He currently serves as a member of the MBrace Therapeutics Scientific Advisory Board.